EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancer

Chiara Benvenuti iD, Alessandro Viansone, Flavia Jacobs, Thomas Grinda, Jean Zeghondy, Mariangela Gaudio, Laura Clapis, Riccardo Gerosa iD, Jacopo Canzian, Caroline Poisson, Meriem Mokdad-Adi, Paola Tiberio und 5 weitere

Tumori Journal · 2026-10 · 112 (5) · 473-477

DOI: 10.1177/03008916261454865 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Tumori Journal, online erschienen am 30.07.2026. Verfasst von Chiara Benvenuti und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Hematology, Breast Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aim There is limited data on the safety of switching between CDK4/6i to address toxicity-related permanent discontinuation in patients with HR+/HER2- advanced breast cancer (ABC). To overcome this issue, this international observational study included consecutive HR+/HER2- ABC patients treated with CDK4/6i at two cancer centers, who switched the CDK4/6i for toxicity. The study aimed to evaluate the safety, feasibility, and clinical impact of this approach. Results Among 1413 patients, 67 (4.5%) switched CDK4/6i due to toxicity. The median time to switch was three months. Adverse events leading to switch were mainly hematologic and hepatic. Recurrence of the same toxicity occurred in 30% of patients, but with lower severity for neutropenia (p=0.047) and hepatotoxicity (p=0.005). Notably, among the 67 patients who switched CDK4/6i, only seven (10%) ultimately required permanent discontinuation of the second CDK4/6i for toxicity, primarily for abemaciclib-induced diarrhea, suggesting that switching may represent a promising strategy to avoid treatment interruption. Median progression-free survival from the start of the first CDK4/6i was 16.8 months Conclusion In conclusion, switching CDK4/6i appears to be a safe and pragmatic strategy to address toxicity-related permanent discontinuation of CDK4/6i.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Erb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsReceptors, ProgesteroneReceptors, EstrogenHumansFemaleMiddle AgedAgedAdultDrug SubstitutionAged, 80 and overAminopyridinesBenzimidazoles

Stichwörter der Autor:innen

CDK4/6 inhibitorsbreast cancerswitchtoxicitytreatment discontinuation

Substanzen

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Erb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsCDK4 protein, humanReceptors, ProgesteroneCDK6 protein, humanReceptors, EstrogenERBB2 protein, humanabemaciclib

Autor:innen und Institutionen

  • Department of Medical Oncology and Hematology, Breast Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
  • Department of Medical Oncology, Gustave Roussy, Villejuif, France.
  • Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Department of Medical Oncology, ASST Papa Giovanni XXIII, Bergamo, Italy.

ORCID-Profile: Chiara Benvenuti, Riccardo Gerosa, Rita De Sanctis

Zitieren

APA

Benvenuti, C., Viansone, A., Jacobs, F., Grinda, T., Zeghondy, J., Gaudio, M., Clapis, L., Gerosa, R., Canzian, J., Poisson, C., Mokdad-Adi, M., Tiberio, P., Saltalamacchia, G., Zambelli, A., Santoro, A., Pistilli, B., & De Sanctis, R. (2026). Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancer. Tumori Journal, 112(5), 473-477. https://doi.org/10.1177/03008916261454865

Vancouver

Benvenuti C, Viansone A, Jacobs F, Grinda T, Zeghondy J, Gaudio M, et al. Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancer. Tumori Journal. 2026;112(5):473-477. doi:10.1177/03008916261454865

BibTeX
@article{Benvenuti2026,
  author = {Benvenuti, Chiara and Viansone, Alessandro and Jacobs, Flavia and Grinda, Thomas and Zeghondy, Jean and Gaudio, Mariangela and Clapis, Laura and Gerosa, Riccardo and Canzian, Jacopo and Poisson, Caroline and Mokdad-Adi, Meriem and Tiberio, Paola and Saltalamacchia, Giuseppe and Zambelli, Alberto and Santoro, Armando and Pistilli, Barbara and De Sanctis, Rita},
  title = {Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancer},
  journal = {Tumori Journal},
  year = {2026},
  volume = {112},
  number = {5},
  pages = {473--477},
  doi = {10.1177/03008916261454865}
}
Kostenlos starten →